216 related articles for article (PubMed ID: 10654652)
1. Further consequences of thioacetazone-induced cutaneous reactions.
Lawn SD; Griffin GE
Int J Tuberc Lung Dis; 2000 Jan; 4(1):92-3. PubMed ID: 10654652
[No Abstract] [Full Text] [Related]
2. Rebuttal: time to call a halt to emotions in the assessment of thioacetazone.
Rieder HL; Enarson DA
Tuber Lung Dis; 1996 Apr; 77(2):109-11. PubMed ID: 8762843
[No Abstract] [Full Text] [Related]
3. Risk factors for adverse drug reactions during thiacetazone treatment of pulmonary tuberculosis in human immunodeficiency virus infected adults.
Okwera A; Johnson JL; Vjecha MJ; Wolski K; Whalen CC; Hom D; Huebner R; Mugerwa RD; Ellner JJ
Int J Tuberc Lung Dis; 1997 Oct; 1(5):441-5. PubMed ID: 9441099
[TBL] [Abstract][Full Text] [Related]
4. Thiacetazone: time to call a halt? Considerations on the use of thiacetazone in African populations with a high prevalence of human immunodeficiency virus infection.
Elliott AM; Foster SD
Tuber Lung Dis; 1996 Feb; 77(1):27-9. PubMed ID: 8733410
[No Abstract] [Full Text] [Related]
5. Wrong drug used for tuberculosis.
Kelly PM
Int J Tuberc Lung Dis; 1997 Aug; 1(4):385. PubMed ID: 9432398
[No Abstract] [Full Text] [Related]
6. Life-threatening cutaneous reactions to thiacetazone-containing antituberculosis treatment in Kumasi, Ghana.
Lawn SD; Frimpong EH; Acheampong JW
West Afr J Med; 1999; 18(4):249-53. PubMed ID: 10734785
[TBL] [Abstract][Full Text] [Related]
7. Tuberculosis in people with HIV.
Bellamy R
Clin Evid; 2005 Dec; (14):858-68. PubMed ID: 16620440
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness and total costs of three alternative strategies for the prevention and management of severe skin reactions attributable to thiacetazone in the treatment of Human Immunodeficiency Virus positive patients with tuberculosis in Kenya.
van Gorkom J; Kibuga DK
Tuber Lung Dis; 1996 Feb; 77(1):30-6. PubMed ID: 8733411
[TBL] [Abstract][Full Text] [Related]
9. Changes in CD4 count with antitubercular therapy in HIV infected children with tuberculosis.
Mukherjee A; Lodha R; Kabra SK
J Trop Pediatr; 2009 Apr; 55(2):125-7. PubMed ID: 18829637
[No Abstract] [Full Text] [Related]
10. Severe hypersensitivity reactions among HIV-seropositive patients with tuberculosis treated with thioacetazone.
Wkly Epidemiol Rec; 1992 Jan; 67(1-2):1-3. PubMed ID: 1371055
[No Abstract] [Full Text] [Related]
11. Treatment of tuberculosis in developing countries.
Pozniak A
Lancet; 1995 Oct; 346(8982):1099. PubMed ID: 7564806
[No Abstract] [Full Text] [Related]
12. Use of thiacetazone.
Wilkinson D; Moore D
Lancet; 1995 Jan; 345(8941):63. PubMed ID: 7528313
[No Abstract] [Full Text] [Related]
13. Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future.
Lehloenya RJ; Dheda K
Expert Rev Anti Infect Ther; 2012 Apr; 10(4):475-86. PubMed ID: 22512756
[TBL] [Abstract][Full Text] [Related]
14. Use of thiacetazone.
Foster S; Kelly P
Lancet; 1995 Jan; 345(8941):62-3. PubMed ID: 7528311
[No Abstract] [Full Text] [Related]
15. Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients.
Morris L; Martin DJ; Bredell H; Nyoka SN; Sacks L; Pendle S; Page-Shipp L; Karp CL; Sterling TR; Quinn TC; Chaisson RE
J Infect Dis; 2003 Jun; 187(12):1967-71. PubMed ID: 12792875
[TBL] [Abstract][Full Text] [Related]
16. "Punctuated" HIV meds planned for TB patients.
AIDS Read; 2001 Jul; 11(7):348, 353. PubMed ID: 11494704
[No Abstract] [Full Text] [Related]
17. Cutaneous hypersensitivity reactions to thiacetazone, HIV infection and thiacetazone concentrations in plasma.
Watkins WM; Mungai M; Muhia DK; Mberu EK; Gathua S; Winstanley PA; Gilks CF; Nunn P
Br J Clin Pharmacol; 1996 Feb; 41(2):160-2. PubMed ID: 8838444
[TBL] [Abstract][Full Text] [Related]
18. Anti-HIV agents. Once-daily anti-HIV therapy in people co-infected with TB.
TreatmentUpdate; 2004; 16(3):4-5. PubMed ID: 17219607
[No Abstract] [Full Text] [Related]
19. Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya.
Hawken M; Nunn P; Gathua S; Brindle R; Godfrey-Faussett P; Githui W; Odhiambo J; Batchelor B; Gilks C; Morris J
Lancet; 1993 Aug; 342(8867):332-7. PubMed ID: 7687729
[TBL] [Abstract][Full Text] [Related]
20. Fatal hepatitis B infection despite immunization in an HIV-infected infant: a possible case of vaccine failure and immune reconstitution inflammatory syndrome.
Van der Linden D; Cotton M; Rabie H; McKerrow N
J Trop Pediatr; 2010 Oct; 56(5):351-4. PubMed ID: 20159888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
